Ambrx has formed a collaboration with Merck & Co., potentially worth US$303 M, to develop biologic-drug conjugates directed at multiple prespecified targets using its EuCODE™ site-specific protein medicinal chemistry technology platform. Unlike other industry alliances for the development of antibody-drug conjugates that have to date been focused on cancer targets, the collaboration is notable in that it also involves targets outside of oncology.